Palovarotene is an investigational drug.
There have been 10 clinical trials for Palovarotene.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 28th 2017.
The most common disease conditions in clinical trials are Myositis Ossificans, Osteophyte, and Osteochondromatosis. The leading clinical trial sponsors are Clementia Pharmaceuticals Inc., Ipsen, and [disabled in preview].
There are fifteen US patents protecting this investigational drug and one hundred and eighty-five international patents.